ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : TNF Receptor
Australian State/Territory : VIC
Clear All
Filter by Field of Research
Medical Virology (4)
Structural Biology (incl. Macromolecular Modelling) (4)
Cell Development, Proliferation and Death (2)
Signal Transduction (2)
Autoimmunity (1)
Cancer Therapy (excl. Chemotherapy and Radiation Therapy) (1)
Cardiology (incl. Cardiovascular Diseases) (1)
Cellular Immunology (1)
Diagnostic radiography (1)
Epidemiology (1)
Medical and Health Sciences not elsewhere classified (1)
Molecular Targets (1)
Nephrology And Urology (1)
Obstetrics and Gynaecology (1)
Oncology and Carcinogenesis (1)
Peripheral Nervous System (1)
Protein Targeting And Signal Transduction (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (27)
Filter by Status
Closed (26)
Filter by Scheme
Project Grants (17)
NHMRC Project Grants (4)
Career Development Fellowships (1)
Ideas Grants (1)
NHMRC Development Grants (1)
NHMRC Postgraduate Scholarships (1)
Program Grants (1)
Research Fellowships (1)
Filter by Country
Australia (26)
Filter by Australian State/Territory
VIC (26)
NSW (4)
ACT (2)
WA (2)
SA (1)
  • Researchers (0)
  • Funded Activities (27)
  • Organisations (0)
  • Funded Activity

    Deadly Commute - Targeting The Trafficking Mechanisms That Licence Inflammatory Cell Death

    Funder
    National Health and Medical Research Council
    Funding Amount
    $774,544.00
    Summary
    MLKL is a protein naturally found inside cells. MLKL is activated by inflammation. Once activated, MLKL relocates to the outer periphery of cells and kills them. Gut cells are especially vulnerable to death-by-MLKL and this problem causes Inflammatory Bowel Disease. Using cutting edge microscopy, we have discovered how MLKL moves to the periphery of cells prior to killing them. We will test if blocking this movement of MLKL to the cell periphery stops gut death and Inflammatory Bowel Disease.
    More information
    Funded Activity

    New Drug Combinations To Enhance Elimination Of Hepatitis B Infection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $888,304.00
    Summary
    We have developed a therapy that kills hepatitis B virus infected cells and promotes elimination of infection. We are now testing novel drugs that can be used to maximise the efficacy of our new treatment to promote better outcomes that may be translated to other infections.
    More information
    Funded Activity

    Regulation Of TNF Expression In Inflammation And Cancer

    Funder
    National Health and Medical Research Council
    Funding Amount
    $728,447.00
    Summary
    By studying a spontaneous mutation in mice, we have found an error in the TNF gene (a major factor in many inflammatory diseases) that causes severe arthritis, heart valve disease and gut inflammation. We have also identified new regulators of TNF expression, which might be useful therapeutic targets to limit inflammation. We intend to study the role of these regulators in controlling the expression of TNF, and the link between chronic inflammation and the development of cancer.
    More information
    Funded Activity

    Interactions Between RAGE And The Type 1 Angiotensin Receptor Determine The Pro-atherosclerotic Actions Of Angiotensin II

    Funder
    National Health and Medical Research Council
    Funding Amount
    $521,956.00
    Summary
    Heart attacks and strokes are a major cause of death and disability in Australians. Activation of the renin angiotensin system plays a key role in the development and progression of atherosclerosis, the process that leads to narrowing and obstruction of arteries. In preliminary data we have found a way to block these pathways without affecting the control of blood pressure. We believe that interventions based on these data will be important for the prevention and treatment of heart disease.
    More information
    Funded Activity

    Spatial And Temporal Dimensions Of Mu-opioid Receptor Signalling: Implications For The Development Of Tolerance

    Funder
    National Health and Medical Research Council
    Funding Amount
    $799,316.00
    Summary
    The use of morphine as an analgesic is still limited by undesirable side effects such as tolerance. Despite decades of research, the mechanisms behind the development of tolerance are poorly understood. The ? opioid receptor is a protein expressed at the surface of the cells that is the target of morphine. This project will investigate the signalling events triggered by opioids with unprecedented resolution and will aim to elucidate why morphine elicits more tolerance than other opioid drugs.
    More information
    Funded Activity

    Structural Events In Insulin And IGF Signalling - A Nanodisc Approach To A Problem In Cancer, Diabetes And Alzheimer's Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $752,403.00
    Summary
    Insulin and its insulin-like growth factors play a major role in three major disease states facing ageing Australians—diabetes, cancer and Alzheimer's disease. We aim to understand how these proteins send messages into cells via their so-called receptors. We will isolate the receptor molecules from cells and then image them in an advanced electron microscope to produce three-dimensional images. Our findings will have implications for the design of therapeutics targeting the above three diseases.
    More information
    Funded Activity

    Development Fo A Novel Treatment For Asthma: The Identification Of Lead Small Molecule Antagonists Of The IL-13/IL-13 Re

    Funder
    National Health and Medical Research Council
    Funding Amount
    $99,750.00
    Summary
    In developed countries Asthma ranks among the most common chronic illnesses. Over two million Australians now have this condition and the cost to our community is estimated to be in excess of $720 million per annum. In 1996 researchers at The Walter and Eliza Hall Institute discovered a new member of the cytokine receptor family, IL-13Ra1, which further research has strongly implicated in the pathology of this disease. The main goal of the proposed research is to discover small molecule antagoni .... In developed countries Asthma ranks among the most common chronic illnesses. Over two million Australians now have this condition and the cost to our community is estimated to be in excess of $720 million per annum. In 1996 researchers at The Walter and Eliza Hall Institute discovered a new member of the cytokine receptor family, IL-13Ra1, which further research has strongly implicated in the pathology of this disease. The main goal of the proposed research is to discover small molecule antagonists of IL-13Ra1 and to identify those suitable for development as novel asthma therapeutics.
    Read more Read less
    More information
    Funded Activity

    The Role Of Advanced Glycation Products (AGEs) And Their Receptors In Diabetic Nephropathy

    Funder
    National Health and Medical Research Council
    Funding Amount
    $83,480.00
    More information
    Funded Activity

    Preclinical Development Of Gene-engineered T Cells For Immunotherapy Of Cancer

    Funder
    National Health and Medical Research Council
    Funding Amount
    $444,500.00
    More information
    Funded Activity

    Targeting The Insulin And Insulin-like Growth Factor Receptors In Cancer, Diabetes And Alzheimer's Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $993,251.00
    Summary
    Diabetes, cancer and Alzheimer's disease are three major diseases facing Australia. This Project will investigate a common point-of-focus of these diseases, namely the interaction of insulin and the insulin-like growth factors with their receptor molecules on the cell surface. It will use recent breakthrough findings by the Chief Investigators to develop new therapeutic approaches for these diseases that could function by targeting these interactions.
    More information

    Showing 1-10 of 27 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback